Abciximab disappoints in AMI shock in PRAGUE-7
Links shared publicly online about this topic.
- 1,783total visits
Abciximab disappoints in AMI shock in PRAGUE-7
Seriously ill patients with acute MI complicated by cardiogenic shock did not benefit from the routine use of abciximab during primary PCI, results of the PRAGUE-7 study show.
View full resource at theheart.org
Tags: Cardiogenic Shock
Most Recently Shared on August 31, 2009 at 4:24 pm By:
heartwire: GP IIb/IIIa inhibitor of no benefit in AMI patients with cardiogenic shock http://bit.ly/1EuajE #ESC09
Advertisement
